tbuckley/cabot-search huggingface dataset:
Risk of Alzheimer’s Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer
Authors: Seo Hyon Baik, Fabricio Sampaio Peres Kury, Clement Joseph McDonald
Journal: Journal of Clinical Oncology (2017)

Purpose To assess the relative risk of Alzheimer's disease (AD) among patients with prostate cancer who received androgen deprivation therapy (ADT), after adjustment for other cancer therapies. Methods Data from demographics, survival, diagnoses codes, procedure codes, and other information about beneficiaries age 67 years or older in the Medicare claims database was assessed to determine the unadjusted and adjusted risks of AD and of dementia from ADT. The prespecified survival analysis method was competing risk regression. Results Of the 1.2 million fee-for-service Medicare beneficiaries who developed prostate cancer in 2001 to 2014, 35% received ADT. Of these, 109,815 (8.9%) and 223,765 (18.8%) developed AD and dementia, respectively, and 26% to 33% died without either outcome. Unadjusted rates of AD and all-cause mortality per 1,000 patient-years were higher among ADT recipients; the unadjusted rates of AD were 17.0 and 15.5 per 1,000 person-years in recipients and nonrecipients, respectively, and the unadjusted rates of all-cause mortality were 73.0 and 51.6 per 1,000 person-years, respectively. The unadjusted rates for dementia in ADT recipients versus nonrecipients were 38.5 and 32.9, respectively, and the unadjusted rates of mortality were 60.2 versus 40.4, respectively. However, after analysis was adjusted for other cancer therapies and other covariates, patients with ADT treatment had no increased risk of AD (subdistribution hazard ratio [SHR], 0.98; 95% CI, 0.97 to 0.99) and had only a miniscule (1%) risk of dementia (SHR, 1.01; 95% CI, 1.01 to 1.02); patients treated with ADT were more likely to die before progression to AD (SHR, 1.24; 95% CI, 1.23 to 1.24) or dementia (SHR, 1.26; 95% CI, 1.25 to 1.26). The risks of AD and dementia were not associated with duration of ADT (ie, no dose effect). Other secondary analyses confirmed these results. Conclusion These data suggest that ADT treatment has no hazard for AD and no meaningful hazard for dementia among men age 67 years or older who are enrolled in Medicare.
Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan
Authors: Meng-Rui Lee, Cheng-Maw Ho, Chih-Hsin Lee, Ming-Chia Lee, Lih-Yu Chang, Kai-Lun Yu, Jen-Chung Ko, Jann-Yuan Wang, Jann-Tay Wang, Li-Na Lee
Journal: European Respiratory Journal (2017)

There are still several unanswered research questions regarding tuberculosis (TB) contact investigations [1–4]. For example, up-to-date epidemiological studies regarding TB contacts in the area of intermediate incidence are not readily available [5]. The long-term risk of TB, especially beyond 5 years, remains undetermined [6]. Risk factors for TB development among contacts are also not well defined [2]. To expand current understanding and knowledge of TB contact investigation, we recruited a population-based TB contacts cohort utilising the National Health Insurance Research Database of Taiwan, which included medical care claims data of 99% Taiwan residents [7]. Taiwan TB contact cohort: 0.5% 1-year yield, age ≥65 as significant risk factor and elevated TB risk at 5th year <http://ow.ly/9ZGr30dpkMc> We acknowledge Lin Hsien-Ho for providing opinions and suggestions on the design and analysis of this epidemiological study.
LDL受容体ノックアウトマウスの頚動脈結さつモデルにおいて、ヘムオキシゲナーゼ‐1過剰発現は新内膜形成および炎症反応を減退させる
Authors: Watanabe Y, Ishikawa K, Kawamura K, Maruyama Y
Journal: Circulation (2002)
Phase I study of vandetinib in combination with gemcitabine and oxaliplatin in advanced solid malignancies.
Authors: Peng Wang, Taofeek Kunle Owonikoko, Yan Lin, Ronald G. Stoller, Daniel P. Petro, Deric M. Park, Ramesh K. Ramanathan, Edward Chu, Jan Hendrik Beumer, Leonard Joseph Appleman
Journal: Journal of Clinical Oncology (2012)

3037 Background: Vandentinib (VAN) is a tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor-2 (VEGFR-2) and 3 (VEGFR-3) as well as epidermal growth factor receptor (EGFR) and RET (‘rearranged during transfection’). Combinations of VEGFR kinase inhibitors and cytotoxic agents have been studied with interest, but have been associated with increased toxicity. This phase I trial evaluated the safety, tolerability and maximum tolerated dose of VAN in combination with gemcitabine (GEM) and oxaliplatin (OX). Methods: Subjects with advanced solid malignancy, ≤ 2 prior regimens with adequate hematologic, hepatic and renal function were eligible. GEM and OX were administered intravenously at 1000 mg/m 2 and 85 mg/m 2 respectively every 14 days. VAN was administered orally at two dose levels: level 1 (200 mg) and level 2 (300 mg) once daily continuously. After a maximum of 6 cycles of GEMOX, non-progressing patients were allowed to continue VAN until progression or intolerance. A dose level was determined to be tolerable if &lt;2 DLTs out of 6 evaluable subjects were observed. Response was assessed by restaging scan after every 2 cycles. Results: A total of 20 subjects were enrolled in the study; 15 male, 5 female. Median age 62 years (47-68). Nine subjects were enrolled on dose level 1 and 11 subjects on dose level 2. One subject in dose level 1 experienced a deep venous thrombosis in cycle 1 deemed a DLT. Thrombocytopenia (worst-grade 3) as well as diarrhea and rash (worst-grade 2) were observed in several patients, without dose-limiting toxicity in cycle 1. Reversible posterior leukoencephalopathy was observed in 1 subject following abrupt self-discontinuation of an antihypertensive mediation. The recommended phase 2 dose was established as GEM (1000mg/m 2 ) OX (85mg/m 2 ) and VAN (300mg). One subject with refractory small cell lung cancer had a confirmed partial response, and 10 subjects (pancreas-7, bladder-2 and biliary-1) achieved stable disease ≥12 weeks. Conclusions: VAN in combination with GEM/OX was well tolerated at full doses of each of the 3 agents. Preliminary anti-tumor activity seen in refractory solid tumors supports further evaluation of this regimen.
Abstract 17435: Undersizing Donor Hearts by Predicted Heart Mass Increases the Risk of Primary Graft Dysfunction Following Cardiac Tranplantation
Authors: Brian Lima, Justin Collier, Joost Felius, Hyunsu Ju, Shelley Hall, Gonzalo Gonzalez-Stawinski
Journal: Circulation (2016)

Background:  Lingering theoretical concern over the hazards of significantly undersized donor hearts has impeded the utilization of otherwise viable allografts for transplantation. Prior studies indicate that predicted heart mass (pHM) provides better size matching in cardiac transplantation than body weight. We examined whether undersizing donor hearts by >30% pHM was associated with primary graft dysfunction (PGD), using the recent ISHLT definition.   Methods:  Using a prospectively maintained clinical database, we reviewed 214 isolated heart transplants at a single institution and compared patients implanted with hearts undersized by >30% versus those implanted with normal donor size hearts within 30% of pHM (control group). Multivariate logistic regression was performed to assess the impact of donor undersizing on the development of mild, moderate, or severe PGD, and in-hospital/30-day mortality.   Results:  The 2 groups were similar in age (56±12 years), history of prior sternotomy (50%), pulmonary vascular resistance (2 Woods units), and ischemic etiology (48%). Significant differences in the undersized vs control groups included a greater proportion of male recipients (100% vs 72%, P 2 , P=0.005). In-hospital/30-day mortality was similar between groups (2.7% vs 3.4%). Overall, the undersized group experienced higher rates of PGD (41% vs 27%) as well as significantly increased rates of moderate/severe PGD (24% vs 9%; P=0.02; Figure 1). Multivariate analysis confirmed that undersizing donor hearts by pHM, but not by donor weight, was predictive of moderate/severe PGD (Odds ratio, 3.1 [95%-CI, 1.2-9.0], P=0.0036).   Conclusions:  Undersized donor hearts by >30% according to pHM may increase rates of PGD following cardiac transplantation. This study confirms that pHM provides more clinically appropriate size matching than weight alone.
Making All Lives Matter in Medicine From the Inside Out
Authors: Michael O. Mensah
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A PEGylated hyaluronic acid conjugate for targeted cancer immunotherapy
Authors: Jung Min Shin, Se Jin Oh, Seunglee Kwon, V.G. Deepagan, Minchang Lee, Seok Ho Song, Hyo-Jung Lee, Suyeon Kim, Kwon-Ho Song, Tae Woo Kim, Jae Hyung Park
Journal: Journal of Controlled Release (2017)
Case 23-2000
Authors: Kenneth H. Mayer, Andrew E. Rosenberg
Journal: New England Journal of Medicine (2000)

Presentation of CaseA 49-year-old man was admitted to the hospital because of pain in the knee.The patient had been in stable health until three months earlier, when he began to have pain in his left knee, which gradually worsened and awakened him during the night. He was referred to this hospital.Twelve years before admission, a motor vehicle accident had resulted in an open fracture of the midshaft of the patient's left tibia, which healed without incident. Three years before admission, the patient was treated elsewhere for severe pneumonia, which was believed to be caused by Pneumocystis carinii. . . .
SPECT, PET, and CTA—Acronyms or Better Imaging?
Authors: Pamela S. Douglas, Leslee J. Shaw
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.
Authors: Dharshan Sivaraj, Michael M. Green, Yubin Kang, David Rizzieri, Louis F. Diehl, Anne W. Beaven, Zhiguo Li, Anderson Garrett, Jackie McIntyre, Gwynn Douglas Long, Nelson Jen An Chao, Cristina Gasparetto
Journal: Journal of Clinical Oncology (2017)

8008 Background: The combination of bendamustine, pomalidomide, and dexamethasone (BPd) displays promising activity in heavily pretreated RRMM. In the Phase I portion, MTD was 120 mg/m 2 bendamustine/3mg pomalidomide/40mg dexamethasone. We report our combined findings from the additional phase II expansion cohort for the first phase I/II trial of BPd in patients with RRMM (NCT01754402). Methods: All patients had to be refractory to prior lenalidomide as well as be pomalidomide naïve, and must have relapsed or have been refractory to their most recent therapy. Treatment consisted of oral pomalidomide PO QD on days 1-21, intravenous (IV) bendamustine given over 30 minutes on day 1, and dexamethasone 40mg on days 1, 8, 15, and 22 of a 28-day cycle. Bendamustine was administered at 120 mg/m 2 for cycle 1, day 1. Results: A total study population of 38 patients was enrolled, with 34 evaluable for toxicity and 32 for efficacy, with 7 patients still receiving treatment. Data cut-off was January 18, 2017. The median age was 67 years, median number of prior regimens was 5, median time from diagnosis was 3.6 years, and median follow-up was 11.7 months. 82% of patients had a prior stem cell transplant, 100% had prior bortezomib, 32% had prior carfilzomib, and all were lenalidomide refractory. Cytogenetic abnormalities included 6 patients with del(17p), 4 with t(4;14), 7 with del(13), and 7 with t(11;14). Patients received a median of 4 cycles of therapy. Best response assessments in 32 evaluable patients showed 3 sCR, 3 VGPR, 17 PR, 7 SD, and 2 PD for an ORR of 72%. The median PFS and OS were 9.6 months and 21.3 months respectively for the entire cohort, with 16 of 32 still alive at follow-up. Grade ≥3 drug-related AEs included fatigue (8%), neutropenia (45%), anemia (26%), thrombocytopenia (24%), and diarrhea (8%). 71% of patients experienced grade ≥3 AEs including neutropenia, anemia, and diarrhea. Conclusions: The BPd regimen is relatively tolerable and achieves a promising overall response rate (ORR of 72%) and durable responses in a heavily pre-treated lenalidomide–refractory population with prior bortezomib exposure, and a median of 5 lines of prior therapy. Clinical trial information: NCT01754402.
亜臨界CO_2によるPGA/PLLA足場中に埋め込まれたHB‐EGFは組織工学腸の産生を増強する【Powered by NICT】
Authors: Liu Yanchun, Nelson Tyler, Cromeens Barrett, Rager Terrence, Lannutti John, Johnson Jed, E Besner Gail
Journal: Biomaterials (2016)
Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015
Authors: David A. Watkins, Catherine O. Johnson, Samantha M. Colquhoun, Ganesan Karthikeyan, Andrea Beaton, Gene Bukhman, Mohammed H. Forouzanfar, Christopher T. Longenecker, Bongani M. Mayosi, George A. Mensah, Bruno R. Nascimento, Antonio L.P. Ribeiro, Craig A. Sable, Andrew C. Steer, Mohsen Naghavi, Ali H. Mokdad, Christopher J.L. Murray, Theo Vos, Jonathan R. Carapetis, Gregory A. Roth
Journal: New England Journal of Medicine (2017)

Rheumatic heart disease remains an important preventable cause of cardiovascular death and disability, particularly in low-income and middle-income countries. We estimated global, regional, and national trends in the prevalence of and mortality due to rheumatic heart disease as part of the 2015 Global Burden of Disease study.We systematically reviewed data on fatal and nonfatal rheumatic heart disease for the period from 1990 through 2015. Two Global Burden of Disease analytic tools, the Cause of Death Ensemble model and DisMod-MR 2.1, were used to produce estimates of mortality and prevalence, including estimates of uncertainty.We estimated that there were 319,400 (95% uncertainty interval, 297,300 to 337,300) deaths due to rheumatic heart disease in 2015. Global age-standardized mortality due to rheumatic heart disease decreased by 47.8% (95% uncertainty interval, 44.7 to 50.9) from 1990 to 2015, but large differences were observed across regions. In 2015, the highest age-standardized mortality due to and prevalence of rheumatic heart disease were observed in Oceania, South Asia, and central sub-Saharan Africa. We estimated that in 2015 there were 33.4 million (95% uncertainty interval, 29.7 million to 43.1 million) cases of rheumatic heart disease and 10.5 million (95% uncertainty interval, 9.6 million to 11.5 million) disability-adjusted life-years due to rheumatic heart disease globally.We estimated the global disease prevalence of and mortality due to rheumatic heart disease over a 25-year period. The health-related burden of rheumatic heart disease has declined worldwide, but high rates of disease persist in some of the poorest regions in the world. (Funded by the Bill and Melinda Gates Foundation and the Medtronic Foundation.).
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Authors: Sarah A Holstein, Sin-Ho Jung, Paul G Richardson, Craig C Hofmeister, David D Hurd, Hani Hassoun, Sergio Giralt, Edward A Stadtmauer, Daniel J Weisdorf, Ravi Vij, Jan S Moreb, Natalie S Callander, Koen van Besien, Teresa G Gentile, Luis Isola, Richard T Maziarz, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H Qazilbash, Cesar Rodriguez, Brian McClune, Robert L Schlossman, Scott E Smith, Vera Hars, Kouros Owzar, Chen Jiang, Molly Boyd, Chelsea Schultz, Marcia Wilson, Parameswaran Hari, Marcelo C Pasquini, Mary M Horowitz, Thomas C Shea, Steven M Devine, Charles Linker, Kenneth C Anderson, Philip L McCarthy
Journal: The Lancet Haematology (2017)
The overloaded right heart and ventricular interdependence
Authors: Robert Naeije, Roberto Badagliacca
Journal: Cardiovascular Research (2017)

The right and the left ventricle are interdependent as both structures are nested within the pericardium, have the septum in common and are encircled with common myocardial fibres. Therefore, right ventricular volume or pressure overloading affects left ventricular function, and this in turn may affect the right ventricle. In normal subjects at rest, right ventricular function has negligible interaction with left ventricular function. However, the right ventricle contributes significantly to the normal cardiac output response to exercise. In patients with right ventricular volume overload without pulmonary hypertension, left ventricular diastolic compliance is decreased and ejection fraction depressed but without intrinsic alteration in contractility. In patients with right ventricular pressure overload, left ventricular compliance is decreased with initial preservation of left ventricular ejection fraction, but with eventual left ventricular atrophic remodelling and altered systolic function. Breathing affects ventricular interdependence, in healthy subjects during exercise and in patients with lung diseases and altered respiratory system mechanics. Inspiration increases right ventricular volumes and decreases left ventricular volumes. Expiration decreases both right and left ventricular volumes. The presence of an intact pericardium enhances ventricular diastolic interdependence but has negligible effect on ventricular systolic interdependence. On the other hand, systolic interdependence is enhanced by a stiff right ventricular free wall, and decreased by a stiff septum. Recent imaging studies have shown that both diastolic and systolic ventricular interactions are negatively affected by right ventricular regional inhomogeneity and prolongation of contraction, which occur along with an increase in pulmonary artery pressure. The clinical relevance of these observations is being explored.
Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid
Authors: Winfred Frazier, Gerald Cochran, Wei-Hsuan Lo-Ciganic, Walid F. Gellad, Adam J. Gordon, Chung-Chou H. Chang, Julie M. Donohue
Journal: JAMA (2017)

This study uses Medicaid data to compare prescription opioid use, duration of opioid use, and rates of medication-assisted treatment (buprenorphine, methadone, or naltrexone) among enrollees before and after an overdose event.
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
Authors: A Tefferi, L Saeed, C A Hanson, R P Ketterling, A Pardanani, N Gangat
Journal: Leukemia (2017)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices
Authors: Osama I.I. Soliman, Sakir Akin, Rahatullah Muslem, Eric Boersma, Olivier C. Manintveld, Thomas Krabatsch, Jan F. Gummert, Theo M.M.H. de By, Ad J.J.C. Bogers, Felix Zijlstra, Paul Mohacsi, Kadir Caliskan
Journal: Circulation (2017)

Background: The aim of the study was to derive and validate a novel risk score for early right-sided heart failure (RHF) after left ventricular assist device implantation. Methods: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) was used to identify adult patients undergoing continuous-flow left ventricular assist device implantation with mainstream devices. Eligible patients (n=2988) were randomly divided into derivation (n=2000) and validation (n=988) cohorts. The primary outcome was early (&lt;30 days) severe postoperative RHF, defined as receiving short- or long-term right-sided circulatory support, continuous inotropic support for ≥14 days, or nitric oxide ventilation for ≥48 hours. The secondary outcome was all-cause mortality and length of stay in the intensive care unit. Covariates found to be associated with RHF (exploratory univariate P &lt;0.10) were entered into a multivariable logistic regression model. A risk score was then generated using the relative magnitude of the exponential regression model coefficients of independent predictors at the last step after checking for collinearity, likelihood ratio test, c index, and clinical weight at each step. Results: A 9.5-point risk score incorporating 5 variables (Interagency Registry for Mechanically Assisted Circulatory Support class, use of multiple inotropes, severe right ventricular dysfunction on echocardiography, ratio of right atrial/pulmonary capillary wedge pressure, hemoglobin) was created. The mean scores in the derivation and validation cohorts were 2.7±1.9 and 2.6±2.0, respectively ( P =0.32). RHF in the derivation cohort occurred in 433 patients (21.7%) after left ventricular assist device implantation and was associated with a lower 1-year (53% versus 71%; P &lt;0.001) and 2-year (45% versus 58%; P &lt;0.001) survival compared with patients without RHF. RHF risk ranged from 11% (low risk score 0–2) to 43.1% (high risk score &gt;4; P &lt;0.0001). Median intensive care unit stay was 7 days (interquartile range, 4–15 days) versus 24 days (interquartile range, 14–38 days) in patients without versus with RHF, respectively ( P &lt;0.001). The c index of the composite score was 0.70 in the derivation and 0.67 in the validation cohort. The EUROMACS-RHF risk score outperformed ( P &lt;0.0001) previously published scores and known individual echocardiographic and hemodynamic markers of RHF. Conclusions: This novel EUROMACS-RHF risk score outperformed currently known risk scores and clinical predictors of early postoperative RHF. This novel score may be useful for tailored risk-based clinical assessment and management of patients with advanced HF evaluated for ventricular assist device therapy.